Vertex Pharmaceuticals (VRTX) stock price, revenue, and financials

Vertex Pharmaceuticals market cap is $47.3 b, and annual revenue was $6.21 b in FY 2020

$47.3 B

VRTX Mkt cap, 12-Nov-2021

$1.7 B

Vertex Pharmaceuticals Revenue Q1, 2021
Vertex Pharmaceuticals Gross profit (Q1, 2021)1.5 B
Vertex Pharmaceuticals Gross profit margin (Q1, 2021), %88.8%
Vertex Pharmaceuticals Net income (Q1, 2021)653.1 M
Vertex Pharmaceuticals EBIT (Q1, 2021)887.8 M
Vertex Pharmaceuticals Cash, 31-Mar-20216.3 B
Vertex Pharmaceuticals EV41.9 B
Get notified regarding key financial metrics and revenue changes at Vertex PharmaceuticalsLearn more
Banner background

Vertex Pharmaceuticals Revenue

Vertex Pharmaceuticals revenue was $6.21 b in FY, 2020 which is a 49.1% year over year increase from the previous period.

Embed Graph

Vertex Pharmaceuticals Revenue Breakdown

Embed Graph

Vertex Pharmaceuticals revenue breakdown by business segment: 12.9% from KALYDECO, 14.6% from ORKAMBI, 10.1% from SYMDEKO/SYMKEVI and 62.3% from TRIKAFTA/KAFTRIO

Vertex Pharmaceuticals Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

3.0b4.2b6.2b

Revenue growth, %

37%49%

Cost of goods sold

409.5m547.8m736.3m

Gross profit

2.6b3.6b5.5b

Gross profit Margin, %

87%87%88%

R&D expense

1.4b1.8b1.8b

General and administrative expense

557.6m658.5m770.5m

Operating expense total

2.0b2.4b2.6b

EBIT

635.2m1.2b2.9b

EBIT margin, %

21%29%46%

Interest expense

58.5m58.2m

Interest income

63.7m22.2m

Pre tax profit

600.2m1.4b3.1b

Income tax expense

(1.5b)218.1m405.2m

Net Income

2.1b1.2b2.7b

EPS

8.14.510.3

Vertex Pharmaceuticals Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

2.7b3.1b6.0b

Accounts Receivable

409.7m633.5m885.4m

Prepaid Expenses

140.8m213.5m308.4m

Inventories

124.4m167.5m280.8m

Current Assets

3.8b4.8b8.1b

PP&E

812.0m745.1m958.5m

Goodwill

50.4m1.0b1.0b

Total Assets

6.2b8.3b11.8b

Accounts Payable

111.0m87.6m155.1m

Short-term debt

9.8m

Current Liabilities

1.1b1.3b1.9b

Long-term debt

581.6m538.6m889.5m

Total Debt

591.4m538.6m889.5m

Total Liabilities

1.8b2.2b3.1b

Common Stock

2.5m2.6m2.6m

Additional Paid-in Capital

7.4b7.9b7.9b

Retained Earnings

(3.0b)(1.9b)858.7m

Total Equity

4.4b6.1b8.7b

Debt to Equity Ratio

0.1 x0.1 x0.1 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x

Financial Leverage

1.4 x1.4 x1.4 x

Vertex Pharmaceuticals Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

2.1b1.2b2.7b

Depreciation and Amortization

72.4m106.9m109.5m

Accounts Receivable

(108.2m)(225.6m)(223.4m)

Inventories

(32.0m)(64.0m)(132.0m)

Accounts Payable

36.6m(22.8m)51.3m

Cash From Operating Activities

1.3b1.6b3.3b

Purchases of PP&E

(95.5m)(75.5m)(259.8m)

Cash From Investing Activities

(202.2m)(1.2b)99.4m

Long-term Borrowings

(33.4m)(39.2m)(42.3m)

Cash From Financing Activities

(71.2m)126.8m(505.3m)

Net Change in Cash

990.7m462.4m2.9b

Interest Paid

66.5m55.6m54.5m

Income Taxes Paid

12.4m24.7m191.8m

Vertex Pharmaceuticals Ratios

USDFY, 2018

EV/EBIT

63.4 x

EV/CFO

31.7 x

Revenue/Employee

1.2m

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.4 x

P/E Ratio

20.5

Vertex Pharmaceuticals Operating Metrics

FY, 2018FY, 2019FY, 2020

Products

456

Vertex Pharmaceuticals Human Capital

Gender

FY, 2020
Male (Board), percent20%
Female (Board), percent13.3%
Male (Senior Leadership), percent20.7%
Female (Senior Leadership), percent12.7%
Male, percent15.7%
Female, percent17.7%

Vertex Pharmaceuticals Employee Rating

3.8637 votes
Culture & Values
3.4
Work/Life Balance
3.3
Senior Management
3.1
Salary & Benefits
4
Career Opportunities
3.1
Source